RU2014135224A - Способ лечения злокачественных опухолей - Google Patents
Способ лечения злокачественных опухолей Download PDFInfo
- Publication number
- RU2014135224A RU2014135224A RU2014135224A RU2014135224A RU2014135224A RU 2014135224 A RU2014135224 A RU 2014135224A RU 2014135224 A RU2014135224 A RU 2014135224A RU 2014135224 A RU2014135224 A RU 2014135224A RU 2014135224 A RU2014135224 A RU 2014135224A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- genotype
- cancer
- vegfa
- nucleotide polymorphism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592893P | 2012-01-31 | 2012-01-31 | |
| US61/592,893 | 2012-01-31 | ||
| US201261654733P | 2012-06-01 | 2012-06-01 | |
| US61/654,733 | 2012-06-01 | ||
| PCT/EP2013/051865 WO2013113796A1 (en) | 2012-01-31 | 2013-01-31 | Method of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014135224A true RU2014135224A (ru) | 2016-03-27 |
Family
ID=47714037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014135224A RU2014135224A (ru) | 2012-01-31 | 2013-01-31 | Способ лечения злокачественных опухолей |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150023953A1 (enExample) |
| EP (2) | EP3045543A3 (enExample) |
| JP (1) | JP2015506955A (enExample) |
| KR (1) | KR20140117644A (enExample) |
| CN (1) | CN104204226A (enExample) |
| AU (1) | AU2013214254B2 (enExample) |
| BR (1) | BR112014019034A8 (enExample) |
| CA (1) | CA2863287A1 (enExample) |
| IN (1) | IN2014DN06127A (enExample) |
| RU (1) | RU2014135224A (enExample) |
| WO (1) | WO2013113796A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109504743A (zh) * | 2017-09-13 | 2019-03-22 | 复旦大学附属华山医院 | 阿帕替尼有效生物标志物vegfr-2基因检测试剂盒 |
| US20230121116A1 (en) * | 2020-01-29 | 2023-04-20 | Board Of Regents, The University Of Texas System | Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| WO1997040462A2 (en) | 1996-04-19 | 1997-10-30 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| CA2413134C (en) | 2000-06-30 | 2010-05-11 | Glaxo Group Limited | Quinazoline ditosylate salt compounds |
| WO2007095038A2 (en) * | 2006-02-09 | 2007-08-23 | Novartis Ag | Mutations and polymorphisms of erbb2 |
| CA2675366A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
| WO2008088893A2 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy |
| EP1980626A1 (en) * | 2007-04-13 | 2008-10-15 | Het Nederlands Kanker Instituut | Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy |
| WO2008128233A1 (en) * | 2007-04-15 | 2008-10-23 | University Of Chicago | Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr) |
| EA027959B1 (ru) * | 2009-08-21 | 2017-09-29 | Смитклайн Бичем (Корк) Лтд. | Способ лечения рака с помощью лапатиниба |
| WO2011060380A1 (en) * | 2009-11-14 | 2011-05-19 | The Regents Of The University Of California | Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer |
-
2013
- 2013-01-31 BR BR112014019034A patent/BR112014019034A8/pt not_active IP Right Cessation
- 2013-01-31 US US14/375,969 patent/US20150023953A1/en not_active Abandoned
- 2013-01-31 EP EP15196262.8A patent/EP3045543A3/en not_active Withdrawn
- 2013-01-31 WO PCT/EP2013/051865 patent/WO2013113796A1/en not_active Ceased
- 2013-01-31 JP JP2014555195A patent/JP2015506955A/ja active Pending
- 2013-01-31 CA CA2863287A patent/CA2863287A1/en not_active Abandoned
- 2013-01-31 RU RU2014135224A patent/RU2014135224A/ru not_active Application Discontinuation
- 2013-01-31 KR KR1020147023977A patent/KR20140117644A/ko not_active Withdrawn
- 2013-01-31 CN CN201380017091.3A patent/CN104204226A/zh active Pending
- 2013-01-31 EP EP13704029.1A patent/EP2809805A1/en not_active Withdrawn
- 2013-01-31 AU AU2013214254A patent/AU2013214254B2/en not_active Ceased
-
2014
- 2014-07-21 IN IN6127DEN2014 patent/IN2014DN06127A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014DN06127A (enExample) | 2015-08-14 |
| BR112014019034A8 (pt) | 2017-07-11 |
| CA2863287A1 (en) | 2013-08-08 |
| EP2809805A1 (en) | 2014-12-10 |
| KR20140117644A (ko) | 2014-10-07 |
| JP2015506955A (ja) | 2015-03-05 |
| CN104204226A (zh) | 2014-12-10 |
| AU2013214254A1 (en) | 2014-08-14 |
| EP3045543A3 (en) | 2016-10-12 |
| AU2013214254B2 (en) | 2016-04-21 |
| EP3045543A2 (en) | 2016-07-20 |
| US20150023953A1 (en) | 2015-01-22 |
| BR112014019034A2 (enExample) | 2017-06-20 |
| WO2013113796A1 (en) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahcene Djaballah et al. | HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target | |
| Parseghian et al. | Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies | |
| Bando et al. | Therapeutic landscape and future direction of metastatic colorectal cancer | |
| Remon et al. | Advanced-stage non–small cell lung cancer: advances in thoracic oncology 2018 | |
| Nielsen et al. | HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | |
| Mukhopadhyay et al. | RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib | |
| US20120130144A1 (en) | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor | |
| Siziopikou et al. | The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies | |
| RU2013114360A (ru) | Биомаркеры и способы лечения | |
| Martinez-Gutierrez et al. | Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy | |
| Chang et al. | Dual HER2 targeted therapy with pyrotinib and trastuzumab in refractory HER2 positive metastatic colorectal cancer: a result from HER2-FUSCC-G study | |
| US20190241968A1 (en) | Biomarker for predicting responsiveness to anticancer agent for gastric cancer and use thereof | |
| Peng et al. | Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma: a big-data intelligence platform-based analysis | |
| RU2017105817A (ru) | Комбинированная терапия | |
| RU2015154985A (ru) | Способы лечения рака | |
| Sheng et al. | Spatial profiling of Patient-Matched HER2 positive gastric cancer reveals resistance mechanisms to Trastuzumab and Trastuzumab Deruxtecan | |
| Liang et al. | The clinicopathological and prognostic value of Nanog in human gastrointestinal luminal cancer: A meta-analysis | |
| RU2007101074A (ru) | Фармацевтическая противораковая композиция пролина или его производных и противоопухолевого антитела | |
| CN119365493A (zh) | 抗-cd84抗体以及其用途 | |
| Fasanaro et al. | Prognostic significance of serine-phosphorylated STAT3 expression in pT1-T2 oral tongue carcinoma | |
| JP2015506955A5 (enExample) | ||
| Panda et al. | A study of the incidence and prognostic value of HER-2 overexpression in patients with gastric adenocarcinoma in Odisha | |
| Lin | Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer | |
| Shao et al. | Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment | |
| Malla et al. | Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170531 |